- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05991791
Intelligent Robotic Interactions for Children With Autism Spectrum Disorders (I-ROBI)
Adapted and Individualized Intelligent Robotic Interactions to the Ability Spectrum of Children With Autism Spectrum Disorder
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Amaria BAGHDADLI, Pr
- Phone Number: 04 67 33 96 96
- Email: a-baghdadli@chu-montpellier.fr
Study Locations
-
-
-
Montpellier, France
- Hôpital La Colombière - CHU de Montpellier
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patient living in the Hérault department (France),
- Patient with a diagnosis of ASD confirmed by a psychiatrist or a psychologist and receiving current care according to the ESDM model in the MPEA Peyre Plantade child psychiatry service.
Exclusion Criteria:
Patients
- Failure to obtain written informed consent after a cooling-off period
- Participating in another type of program other than ESDM
- Not being affiliated to a French social security system or being a beneficiary of such a system
Therapist
- History of epilepsy for health professionals (therapists)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Children with autism spectrum disorders
|
Phase A
Phase B :
Phase C :
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Score of success on the selected task in the ESDM program
Time Frame: From phase A (baseline) to phase C (post-intervention) = 19 weeks
|
Measure the success score for the selected task using the ESDM scoring grid.
As soon as the child successfully completes one of the different learning stages, a success score is given to the task.
This score will be maximum if all the learning stages of the task considered have been reached (Task 1 = 6 learning stages (maximum score =6); Tasks 2 and 3 = 7 stages (maximum score =7)).
The ESDM scoring grid will be completed by the research therapists at the end of each session.
|
From phase A (baseline) to phase C (post-intervention) = 19 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time of the child's viewing and movement of the head and body towards the robot (task 1: saying "hello")
Time Frame: During Phase B = 11 weeks
|
Measurement of the viewing and movement times toward the robot, as well as the response time from the analysis of the videos made during the sessions using the Pepper robot. Data from the robot: - Video recording by camera of the sessions of the whole room (camera independent of the robot) - Video return by the camera installed on the robot - Audio feedback from the therapist, the robot and the child. |
During Phase B = 11 weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Time of the child's viewing and movement of the head and body towards the therapist (task 1: saying "hello")
Time Frame: From phase A (baseline) to phase C (post-intervention) = 19 weeks
|
Measurement of the viewing and movement times toward the therapist, as well as the response time from the analysis of the videos made during the sessions using the Pepper robot. Data from the robot: - Video recording by camera of the sessions of the whole room (camera independent of the robot) - Video return by the camera installed on the robot - Audio feedback from the therapist, the robot and the child. |
From phase A (baseline) to phase C (post-intervention) = 19 weeks
|
Response time of the child after the presentation of the imitation exercise (task 2: action imitation)
Time Frame: From phase A (baseline) to phase C (post-intervention) = 19 weeks
|
Measurement of the child's response time during the imitation exercise
|
From phase A (baseline) to phase C (post-intervention) = 19 weeks
|
Number of objects given to the robot (task 3 : give an object on verbal request)
Time Frame: From phase A (baseline) to phase C (post-intervention) = 19 weeks
|
Measurement of the number of objects given out of the 5 requested (best score 5/5) in task 3.
|
From phase A (baseline) to phase C (post-intervention) = 19 weeks
|
Teleoperation success score for therapist (throught UX score)
Time Frame: Phase C (from week 5 to 15)
|
Measurement of the success score (UX) of the teleoperation using the videos of the Pepper robot and according to the successful tasks to be performed during the session (the child and the second practitioner in the room can clearly hear the robot's instructions, the robot's gestures are fluid and is able to point to objects with the hand…).
If the therapist was able to initiate each task, the score is 3/3.
|
Phase C (from week 5 to 15)
|
Parent satisfaction score on current care
Time Frame: During phase A (to 4 weeks), Phase B (to 15 weeks), Phase C (to 19 weeks).
|
Measurement of satisfaction score using a numerical satisfaction scale (EN).
Parents will be asked about their current satisfaction with the care after each phase of the procedure.
This will be rated on a scale of 0 to 10, (0 "I am not at all satisfied with the effectiveness of the proposed care" and 10 "I am totally satisfied with the care").
|
During phase A (to 4 weeks), Phase B (to 15 weeks), Phase C (to 19 weeks).
|
Professional satisfaction score on current care.
Time Frame: During phase A (to 4 weeks), Phase B (to 15 weeks), Phase C (to 19 weeks)
|
Measurement of satisfaction score using a numerical satisfaction scale (EN).
Professionals will be asked about their current satisfaction with the care after each phase of the procedure.
This will be rated on a scale of 0 to 10, (0 "I am not at all satisfied with the effectiveness of the proposed care" and 10 "I am totally satisfied with the care").
|
During phase A (to 4 weeks), Phase B (to 15 weeks), Phase C (to 19 weeks)
|
Score of success in the ESDM tasks without teleoperation
Time Frame: During phase A (to 4 weeks), Phase C (from week 16 to 19
|
This score (observe/total) will be maximum if all the learning stages of the task in question have been reached (Task 1 = 6 learning stages (maximum score =6); Tasks 2 and 3 = 7 stages (maximum score = 7)).
This scoring will be done by therapist at the end of each intervention, after the current care.
|
During phase A (to 4 weeks), Phase C (from week 16 to 19
|
Score of success in the ESDM tasks with teleoperation
Time Frame: During phase B (from week 5 to 15)
|
This score (observe/total) will be maximum if all the learning stages of the task in question have been reached (Task 1 = 6 learning stages (maximum score =6); Tasks 2 and 3 = 7 stages (maximum score =7)).The robotics analyses will be performed by a robotic engineer of the LIRMM independent to the project.
|
During phase B (from week 5 to 15)
|
Teleoperation usability score for therapist (throught UMUX score)
Time Frame: During phase A (to 4 weeks), Phase B (to 15 weeks), Phase C (to 19 weeks)
|
A User Experience Questionnaire (UMUX) was administered at weeks 5, 10 and 15 to assess the quality and ease of use of the teleoperation system over time.
The questionnaires are evaluated on a scale from 0 (minimum score) to 10 (maximum score).
0=Not at all satisfied 10= Totally satisfied
|
During phase A (to 4 weeks), Phase B (to 15 weeks), Phase C (to 19 weeks)
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- RECHMPL23_0056
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Autism Spectrum Disorder
-
Stanford UniversityCalifornia Department of Developmental ServicesRecruitingAutism Spectrum Disorder | Autistic Disorder | Autism | Autism Spectrum Disorders | Autistic Disorders Spectrum | Autistic Spectrum Disorder | Autistic Spectrum DisordersUnited States
-
Centre Hospitalier Intercommunal Robert BallangerRecruitingAutism Spectrum Disorder (ASD)France
-
Hoffmann-La RocheCompletedAutism Spectrum Disorder (ASD)United States, Canada, Italy, Spain
-
Axial Therapeutics, Inc.Active, not recruitingAutism Spectrum Disorder (ASD)United States, Australia, New Zealand
-
Technion, Israel Institute of TechnologyCompleted
-
Stanford UniversityNational Institute on Deafness and Other Communication Disorders (NIDCD)CompletedAutism | Autism Spectrum Disorder (ASD)United States
-
Corporacion Parc TauliUnknown
-
Massachusetts General HospitalWithdrawnDouble-blind Trial of Buspirone for the Treatment of Anxiety in Youth With Autism Spectrum DisordersAutism Spectrum Disorder (ASD)United States
-
Institut de Recherches Internationales ServierADIR, a Servier Group companyTerminatedAutism Spectrum Disorder (ASD)Spain, United States, Hungary, Poland, Australia, United Kingdom, Brazil, Czechia, France, Italy, Portugal, Slovakia
-
Florida Gulf Coast UniversityCompletedAutism Spectrum Disorder High-FunctioningUnited States
Clinical Trials on Early Start Denver Model (ESDM)
-
Duke UniversityNational Institute of Mental Health (NIMH); University of Cape TownCompletedAutism Spectrum DisorderSouth Africa
-
Hôpital le VinatierHospices Civils de Lyon; University Hospital, Strasbourg, France; Versailles... and other collaboratorsCompletedAutism Spectrum DisorderFrance
-
Duke UniversityUniversity of Cape TownCompletedAutism Spectrum DisorderSouth Africa
-
University of California, DavisNational Institute of Mental Health (NIMH)Recruiting
-
University of California, DavisUniversity of California, Los Angeles; University of Washington; Vanderbilt UniversityCompletedAutism Spectrum DisorderUnited States
-
Hôpital le VinatierTerminatedAutism Spectrum DisorderFrance
-
Bar-Ilan University, IsraelAssociation for Children at RiskUnknown
-
Vanderbilt University Medical CenterCompletedStress | Autism Spectrum Disorder | ParentsUnited States
-
Bruno RhinerUniversity of Arkansas; West Virginia UniversityActive, not recruiting
-
University of California, DavisNational Institute of Mental Health (NIMH); University of California, Los Angeles and other collaboratorsCompletedAutism Spectrum Disorder | AutismUnited States